진매트릭스

본문 바로가기
Search

Natural Biomaterial Discovery Technology

Core technology for discovery and
development of Pharmaceutically active
ingredients from natural materials

Technology Overview

Natural products including plants, animals, minerals, microorganisms and their metabolites have been used as food and medicine for a long time. Not only they have accumulated much clinical experience, but also are known as a source of an unlimited number of active substances that can replace synthetic chemical drugs.
GeneMatrix has core technologies for identifying pharmaceutically active new materials from natural products.
Through this, we develop various health functional foods 1) (dietary supplements), health foods and herbal medicines.

  • Development Process

1) 'Health functional food (Dietary supplement)' is a food manufactured using objectively and scientifically recognized raw materials or ingredients with useful functions for human body, with marked certification and words about functionality on the label.

2) 'Functional materials' can be divided into 'generic materials' that is notified by the Korean Ministry of Food and Drug Safety and can be used by anyone, and 'product specific materials' that are independently verified by and exclusive to the developer.

Raw Materials from Wheatgrass Extract

Our natural pharmaceutical material GM-T is a wheatgrass extract, which has no side effects from taking, and has been shown to excellently reduce liver inflammation, alleviate liver fat, and reduce weight and fat in animal tests. GM-T is directly involved in lipid metabolism and is an excellent material to fundamentally improve obesity and fatty liver.

GM-T is in the process of clinical trial stage of "liver health" functionality and will enter the clinical trial of "body fat reduction" functionality. It will be introduced to the market exclusively as a product specific health functional food.

GM-T Development Stages

Product code Marker component → Standardization of raw materials →
Establishment of specification
Clinical Trial MFDS Approval Launching
In vitro In vivo
GM-T-101
Reduction of cellular fat Inhibition of cellular fat synthesisSecuring the cell safety Improvement on liver inflammation Improvement on fatty liver Improvement on blood lipid Reduction of lipogenic gene expression Improvement on insulin resistance Ensuring the animal safety Entered into clinical trial    
GM-T-202
Reduction of cellular fat Inhibition of cellular fat synthesis Securing the cell safety Reduction of body fat Improvement on blood lipid Reduction of lipogenic gene expression Improvement on insulin resistance Ensuring the animal safety Preparing for clinical trial    

Patents

Composition containing triticum aestivum lamarck extracts or fraction thereof as an active ingredient (Registration No.10-1160575)
A composition comprising of a sprout extract of Triticum aestivum for treating and preventing obesity disease (Registration No.10-1277266)
A composition for prevention or improvement of nonalcoholic fatty liver disease containing Triticuma estivum extract as an active ingredient (Application No. 10-2017-011600)

Key Findings

  • Liver inflammation improvement effect of GM-T

  • Fatty liver improvement effect of GM-T

  • Weight loss effect of GM-T

  • Formulation of GM-T for clinical trials


Copyright 2018 © Genematrix Inc., All rights reserved.

Copyrights 2018 ⓒ Genematrix. co.ltd., All rights reserved.